Polymorphisms in the PNMT gene
AssigneeCity of Hope
InventorsDavid E. Comings, James P. MacMurray
Life of this patent
Estimating the term…
Abstract
The present invention is directed to two single nucleotide polymorphisms, identified as G-182A and G-387A, in the promoter region of the human phenylethanolamine N-methyltransferase (PNMT) gene, the gene products thereof, and to methods for the determination (diagnosis) of susceptibility to (risk of) neurologic or neuropsychiatric diseases involving adrenergic neurons.
Claims6
A method of determining a risk in an individual for a neurological or neuropsychiatric disorder, wherein said disorder is selected from the group consisting of, early onset Alzheimer's Disease, Multiple Sclerosis, bipolar disorder, schizophrenia and attention deficit hyperactivity disorder, which comprises determining the genotype of an individual by analyzing polymorphisms at nucleotide positions -387 and -182 of the PNMT gene and correlating the genotype with a predetermined risk for said disorder.
Dependencies are inferred from the claim text.